Summary.-Comparisons between oestrogen-receptor (RE)-positive or negative patients were made on a continuous series of 735 patients with primary breast tumours seen at the major treatment centre in British Columbia between 1975 and 1978. RE positivity was commoner in older patients, and was not associated with menopausal status independently of age. The concentration of receptor protein also increased with increasing age, but was not affected by menopausal status. Neither RE status nor quantity was associated with any of the epidemiological risk factors studied, which included parity, age at first birth, weight, family history and exposure to oestrogenic drugs and oral contraceptives. Patients with RE-tumours were more likely to present with symptoms other than a breast lump, pain or nipple inversion, and had less-differentiated tumours; they did not differ from RE+ patients in terms of stage, size of tumour, or interval from first symptom. These findings are discussed in terms of the biological origin and determinants of oestrogen receptors.
BREAST-CANCER PATIENTS with oestrogen-receptor-positive (RE+) tumours differ from those with RE-tumours in their response to hormonal therapy (McGuire, 1978) , survival from diagnosis (Bishop et al., 1979) , time to first recurrence (Cooke et al., 1979; Knight et al., 1977) and probably in their response to chemotherapy (Lippman et al., 1978; Kiang et al., 1978) . Oestrogen positivity has also been reported to vary with menopausal status (Allegra et al., 1979) , age (Fisher et al., 1980) , ethnic origin (Nomura et al., 1977) and features of tumour such as histological grade , degree of elastosis (Masters et al., 1978) , pathological type (Rosen et al., 1975; Kern, 1979) and cell-doubling time (McGuire, 1978) . A report based on 45 patients suggests that RE-tumours are more common in women who have had an oophorectomy and have used oestrogenic drugs (Wallace et al., 1978) . These many studies, each examining only a few factors, led us to 45 consider a general hypothesis of systematic differences between the characteristics of either the tumour or the patient in association with RE status or quantity. If RE status reflects distinct differences, either in the host or in the pathogenic mechanisms of the tumour, there may be differences in RE status in terms of known risk factors for breast cancer, and in the clinical and pathological features of the tumour, particularly those which may reflect tumour activity, such as the staging at diagnosis and the interval between first symptom and diagnosis.
Accordingly, from a large continuous series of patients referred to a major treatment institution, we abstracted data on RE status, and recognized breast-cancer risk factors, and major clinical and pathological characteristics. In keeping with epidemiological principles, but in contrast to many previous studies, we have assessed the associations between RE status and each of these characteristics, taking into account the confounding effects of other factors, of which the most important is age.
METHODS
Sources of data.-From the patient indices at the A. Maxwell Evans Clinic in Vancouver and at the oestrogen receptor laboratory of the Vancouver General Hospital, we identified all patients who were referred to the clinic for initial treatment of a primary breast tumour between 1975 and 1978 and who had an oestrogen-receptor (RE) assay performed: a total of 735 patients. All RE assays were performed in the same laboratory under the supervision of W.G. An admission-interview record of standardized design was completed on all patients, and life-long follow-up instituted. The records of these patients were abstracted and coded in a standardized manner by two abstractors, and the data on RE status supplied independently from the laboratory.
Laboratory methods.-Whole tumours were frozen, transported (Muschenheim et al., 1978) and stored in liquid N2 or at -80°C. Tumour tissue (0-2-0-5 g) was pulverized in a Mikro-Dismembrator (B. Braun Melsungen AG, W. Germany) (Wagner & Jungblut, 1976) and the powder reconstituted with 2-5 ml of cold TED buffer (10 mM Tris-HCl, 195 mM EDTA, 0-5 mM dithiothreitol, pH 7.5) and centrifuged at 39,000 g, 0°C, for 15 min. Group, 1973) . A piece of tumour representative of that used for receptor analysis was placed in buffered formalin and processed for microscopic histology.
Analyses of a rat-uteri quality-control pool over 1 year indicated that the precision of the receptor assay was about 15% at a mean level of 100 fmol/mg protein with a within-run precision (as measured by the difference between duplicates) of 7%.
Tumours were considered to be RE+ if they had a BI > 40% and specific binding > 6 fmol/mg cytosol protein. Those tumours with a BI <20% and specific binding <3 fmol/ mg cytosol protein were considered RE-; this was the highest seen in non-target and normal breast tissue. Values falling between these limits were considered indeterminate. These limits are about equivalent to those used by other investigators (McGuire et al., 1975; Allegra et al., 1978; DeSombre et al., 1978) .
Statistical methods-.The association between RE positivity, determined as above, and menopausal status was assessed by the Mantel-Haenszel test (Mantel & Haenszel, 1959) and that with age by Mantel's test for trend (Mantel, 1963) ; these both yield a x2 statistic with 1 d.f. and allow adjustment for a covariate by stratification. Quantitative data on RE concentrations were analysed using the non-parametric Savage statistic (Savage, 1956 These patients were functionally premenopausal, and so an analysis was done combining these patients with the premenopausal group. This again showed no association between RE status and menstrual status when age is controlled. The hysterectomized group of patients had median RE concentrations of 7, 39 and 53 fmol/mg at ages 35-44, 45-54 and 55-64 years, respectively, thus showing similar levels to those of menstruating and of functionally menopausal women, and a similar increase with age.
For patients within the age range 40-59 years, the RE+ rates were 62% in those < 2 years postmenopausal, 68% in those 3-5 years, and 76% in those 6 or more years postmenopausal; this trend in positivity persisted after adjustment for age differences, but was not statistically significant. Quantitative analysis showed no association of RE concentration with menopausal status, categorized as above, after age adjustment (X2 trend= 0X04, P=0.8) while again showing a significant association with age controlled for menopausal status (X2 trend= 10-3, P=0-0001).
Associations with breast-cancer risk factors
There was no significant association of RE status with age at menopause, type of menopause, or prior oophorectomy (Table  II) . Age at menarche showed no significant association when examined in categories of < 12, 13, and 14+ years, but comparison of the 14 + category with all others gave an odds ratio of IP75 (X2 = 4.4, P < 0.05); such reclassification after preliminary examination of the data compromises the usual statistical tests and little weight can be given to this result. There were no significant associations with ethnic origin, marital status, parity or age at first birth although, again, comparison of the small group of women whose first birth was at or before age 19 with all other gravid women yielded an odds ratio of 0 49 (X2 = 4 0, P < 0 05). There were no significant associations with socio-economic status, weight, a family history of breast cancer in first-degree relatives, or a (Table III) . Symptoms other than a painless lump tended to occur in association with an RE-tumour, though this was significant only for the "other" group, where the agecorrected odds ratio was 0-56 (x2 = 4 4, P < 0 05). There was no difference in the interval from first symptom to diagnosis, and no difference in the size of the tumour, the number of positive axillary nodes, or the presence of metastases. Pathological grading was available on only 61% of patients (further review is in progress); poorly differentiated or anaplastic tumours were significantly less likely to be RE+ (odds ratio 0-36, x2=17-6, P<0*0001).
The median RE protein concentration was not significant (X 2 = 0 2, P = 0 7).
DISCUSSION
The proportion of RE+ tumours increased steadily from young ages to a peak at ages 60-74, and then fell slightly. This slight drop at older ages was less apparent if an absolute cut-off value of RE protein concentration was used, as the proportion of tumours with an indeterminate RE level rose at ages over 70. The smooth increase in positivity with age was broken only by a peak at ages 45-49. This relationship of RE status to age explained the indirect association to menopausal status; the high proportion of RE+ tumours in postmenopausal women was due to their older age, rather than to their menopausal status, and in premenopausal and postmenopausal patients of similar ages the proportions with RE+ tumours were similar. Most studies show that postmenopausal women have higher RE+ rates than do premenopausal women, but few have assessed whether this is due to their postmenopausal status or to their being older. Allegra et al. (1979) did so on 328 patients and concluded that age had no effect, within menopausal categories; however, their data do show positive associations of RE concentration with age for pre-and postmenopausal patients separately, and their conclusion is based on their failure to detect a statistically significant effect of age, a finding which reflects sample size as well as the true association. They did not assess whether menopausal status was related to RE content after adjusting for age. Fisher et al. (1980) studying 178 patients reported a strong association of RE status with age, and a weaker one with menstrual status; again they did not attempt to separate the two effects but their data suggest that the age association is the stronger.
It is unlikely that the differences in RE+ at various ages are due simply to differences in the concentration of circulating or tissue oestradiol and consequent saturation of receptor. While conflicting results are produced by analyses which combine data from both premenopausal and postmenopausal women (Sakai & Saez, 1976; Theve et al., 1978; Meyer et al., 1979; Nagai et al., 1979) , data from postmenopausal women analysed separately show a positive correlation between plasma oestrogen and tumour RE (Saez et al., 1978) . No correlation has been found between tissue and plasma oestradiol concentrations (Nagai et al., 1979) , or between high oestrogen levels in tumour cytosol fractions and low RE content (Fishman et al., 1977) . Although very high levels of endogenous hormone potentially result in low RE values (Meyer et al., 1979 (Meyer et al., , 1978b Garola & McGuire, 1977; Horwitz & McGuire, 1978) and higher levels of progesterone in the premenopausal state may limit oestrogen stimulation of RE synthesis (Saez et al., 1978) it is unlikely that false RE-assays will result (Sakai & Saez, 1976; Fishman et al., 1977; Hahnel & Twaddle, 1979) . The RE content of mammary tumours is inversely related to the proliferative rate as measured by the dT-labelling index (Meyer et al., 1977 (Meyer et al., , 1978a Silvestrini et al., 1979) . Tumours from young women have higher dTlabelling indices and lower RE than tumours from older women (Meyer et al., 1978a) but differences in plasma oestrogen levels do not account for this association (Meyer et al., 1977) . Meyer et al. (1979) have suggested that one type of breast cancer, characterized by rapid proliferation and low RE, occurs predominantly in younger women and another, characterized by slow cell proliferation and high RE, occurs predominantly in older women.
Our data show no association between RE+ or the concentration of receptor protein and age at menarche, age at menopause, ethnic origin, parity, age at first birth, socio-economic status, weight and family history. All these factors are risk factors for breast cancer, and most theories of their mode of action as risk factors involve hormonal mechanisms. For some factors, such as ethnic origin, our failure to find a significant difference might only reflect small numbers, but for most factors the numbers of patients in each category examined are quite large, and there is little suggestion of any association with RE status. So if the higher risk of breast cancer in women with a late first birth than in those with an early first birth, for example, is due to a difference in endogenous hormonal milieu, that difference does not show itself in terms of a different type of breast tumour as assessed by RE status. We also found no association of RE status with factors reflecting major changes in hormonal exposure, such as oophorectomy or the use of oral contraceptive or oestrogenic drugs. Wallace et al. (1978) reported, after study- mon in those with RE-tumours; we have failed to confirm this. The importance of controlling for age is great in such studies; if no age control is made, our data show that RE-tumours are much more common in users of oral contraceptives, but this is entirely due to their younger age.
We found no difference between RE+ and RE-patients in terms of the interval from symptom to diagnosis, or staging at diagnosis. Thus the reported more aggressive behaviour and higher tumour-doubling rate (McGuire, 1978) of RE-tumours is insufficient to produce a difference in the extent of disease at diagnosis. However, the RE-tumours were less differentiated.
Despite the similarities in terms of the risk factors studied, the distribution of age at diagnosis is quite different for RE+ and RE-tumours. -~~~ reported is a consecutive series and, although it is not truly representative of a population based incidence series of the disease due to factors affecting referral to the institution, there is no reason why these referral biases should work differently for RE+ and RE-patients. It is therefore possible to apply the RE+ percentages by age from this series to incidence data for the same population (Ministry of Health of British Columbia, 1976) to construct age-incidence curves for RE+ and RE-tumours independently (Fig. 3) . The incidence-age relationship for each tumour type consists of two components; at younger ages the incidence rises about 25% per year of age, whereas at older ages it rises only about 2% per year. The difference between the curves is produced by the incidence of RE+ tumours rising more rapidly than that of RE-tumours, at ages below 45, and by this steep rise continuing for 5 years longer for RE+ tumours before changing to the lower rate of increase characteristic of older women. In Japanese, as compared to North American populations, the incidence of breast cancer is lower and this difference is much greater in older women;
in fact the curve of total breast-cancer incidence against age from combined Japanese registry data (Fujimoto et at., 1979 ) is similar to that of RE-tumours in British Columbia (Fig. 4) . The proportion of RE+ tumours in Japanese series appears not to change with age or with menopausal status (Nomura et al., 1977) , thus curves for RE+ and RE-tumours in Japanese patients would be similar to the combined incidence curve in Fig. 4 . This suggests that the factors producing the difference in breast-cancer incidence between Japanese and western populations may particularly affect the incidence of RE+ tumours.
